agenus
doses
first
patient
inkt
cell
therapy
allogeneic
shelf
inkt
cell
therapy
targets
patients
moderate
severe
inkt
cells
designed
clear
virus
reducing
harmful
inflammation
lexington
globe
newswire
agenus
nasdaq
agen
company
extensive
pipeline
agents
designed
activate
immune
response
cancers
infectious
diseases
announced
dosing
first
patient
allogeneic
cell
therapy
subsidiary
agentus
therapeutics
trial
led
koen
van
besien
weill
cornell
medical
college
new
york
presbyterian
hospital
separately
fda
also
cleared
treat
patients
cancer
cancer
trials
expected
commence
shortly
pleased
advance
proprietary
inkt
cell
therapy
efforts
address
pandemic
said
walter
flamenbaum
ceo
agentus
therapeutics
trial
designed
treat
patients
moderate
severe
symptoms
cells
potential
clear
virus
dampen
harmful
inflammation
prevent
inkt
cell
therapy
offers
new
promise
fight
solid
tumor
cancers
well
said
garo
armen
chairman
ceo
agenus
inkts
penetrate
tissues
giving
critical
advantage
targeting
solid
tumors
currently
served
approved
cell
therapies
inkts
also
demonstrated
curative
potential
preclinical
cancer
models
refractory
available
therapies
product
designed
treat
patients
affordably
subsidiary
agenus
agentus
currently
unique
access
agenus
portfolio
checkpoint
antibodies
cancer
vaccines
allows
optimal
combinations
cell
therapies
gives
company
enormous
flexibility
develop
effective
combinations
curative
potential
patients
cancer
infectious
disease
significant
cost
advantage
agentus
therapeutics
agentus
therapeutics
biopharmaceutical
company
focused
discovery
development
commercialization
breakthrough
unmodified
modified
allogeneic
inkt
cells
engineered
receptors
cell
receptors
tcrs
chimeric
antigen
receptors
cars
designed
supercharge
human
immune
system
cells
seek
destroy
cancer
agentus
also
aims
advance
adoptive
cell
therapy
formats
would
enable
living
drugs
agentus
locations
lexington
cambridge
uk
information
please
visit
agenus
agenus
company
focused
discovery
development
therapies
engage
body
immune
system
fight
cancer
company
vision
expand
patient
populations
benefiting
cancer
immunotherapy
pursuing
combination
approaches
leverage
broad
repertoire
antibody
therapeutics
adoptive
cell
therapies
agentus
therapeutics
subsidiary
proprietary
cancer
vaccine
platforms
company
equipped
suite
antibody
discovery
platforms
gmp
manufacturing
facility
capacity
support
clinical
programs
agenus
headquartered
lexington
information
please
visit
twitter
handle
information
may
important
investors
routinely
posted
website
twitter
statements
press
release
contains
statements
made
pursuant
safe
harbor
provisions
federal
securities
laws
including
statements
regarding
anticipated
commencement
cell
therapy
clinical
trials
cancer
expected
benefits
observed
trials
cell
therapy
treatments
generally
statements
subject
risks
uncertainties
could
cause
actual
results
differ
materially
risks
uncertainties
include
among
others
factors
described
risk
factors
section
recent
quarterly
report
form
annual
report
form
filed
securities
exchange
commission
agenus
cautions
investors
place
considerable
reliance
statements
contained
release
statements
speak
date
press
release
agenus
undertakes
obligation
update
revise
statements
extent
required
law
statements
expressly
qualified
entirety
cautionary
statement
